礼来与信达生物达成捷帕力(匹妥布替尼片)中国大陆商业化协议

美港电讯
16 Dec 2024

【礼来与信达生物达成捷帕力(匹妥布替尼片)中国大陆商业化协议】金十数据12月16日讯,礼来(LLY.N)12月16日和信达生物制药集团共同宣布就礼来非共价(可逆)BTK抑制剂捷帕力(匹妥布替尼100毫克和50毫克片剂)在中国大陆的权益达成以下合作协议:信达生物将负责捷帕力 的进口、销售、推广和分销工作;礼来将负责捷帕力 的研发和上市后医学事务相关工作。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10